Those Covid-19 variants? ‘Don’t worry yet,’ vaccine expert says
Paul Offit, the vaccine developer, explains why there’s enough evidence to make it an issue worth watching, nonetheless.
Related Articles
Animal rights group urges SEC to investigate Charles River over monkey purchases
PETA has asked securities regulators to investigate Charles River Laboratories for allegedly misleading investors about its sales and purchases of long-tailed macaques.
ARCH, Medicines Co. veterans raise $290 million for in-licensed obesity drugs
After scouring 200 companies’ pipelines, a new biotech firm is launching with one of the most wide-ranging pipelines yet for obesity drug development.
Cancer vaccine startup launches with $54 million, Spark veteran as CEO
A new startup focused on creating vaccines for cancers, influenza, and potentially even HIV launched Thursday with $54 million in funding.
Cerevel drug for Parkinson’s disease improved symptom control in trial
Cerevel Therapeutics, which AbbVie is acquiring, said Thursday its drug tavapadon, taken with the common Parkinson’s drug levodopa, showed positive results in controlling motor symptoms.
Medicaid should cover donor breast milk for vulnerable infants
Expanding Medicaid coverage of donor breast milk would save lives. Research shows it would also save taxpayers up to $60 million a year.
Microsoft is selling AI in health care, and helping to set its standards. Is that a problem?
For some, Microsoft’s deep involvement in setting standards for the use of AI in health care raises questions about “regulatory capture.”
How BIO CEO’s cozy relationship with WuXi soured
As lawmakers take aim at WuXi Apptec, the issue is testing the ability of BIO’s CEO to navigate a domestic policy issue that is tangled…
Health disparities and premature deaths run deep, even in best-performing states
A new analysis of health inequities shows that every state has deep racial and ethnic disparities in the performance of their health care systems.
Second-generation mosquito nets prevented 13 million malaria cases in large pilot programs
Second-generation mosquito nets prevented 13 million malaria cases and 25,000 deaths in large pilot programs.
Teladoc became a household name under Jason Gorevic. Investors wanted more
Gorevic’s departure follows a series of missed financial projections, a precipitous decline in Teladoc’s stock price, and an uninspired vision for its future.